Helixmith Co Ltd (084990 ፦ ) የአክሲዮን ዋጋ እና ዜና

(KRW)	ዲሴም 2024	ከዓመት ዓመት ለውጥ
ገቢ	1.63 ቢ	203.14%
የሥራ ወጪ	2.28 ቢ	-65.70%
የተጣራ ገቢ	-1.96 ቢ	94.61%
የተጣራ የትርፍ ክልል	-120.28	98.22%
ገቢ በሼር	—	—
EBITDA	-280.49 ሚ	92.01%
ውጤታማ የግብር ተመን	—	—

ቀሪ ሒሳብ ሉሆች

አጠቃላይ ንብረቶች

አጠቃላይ ተጠያቂነቶች

(KRW)	ዲሴም 2024	ከዓመት ዓመት ለውጥ
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ	76.11 ቢ	-33.22%
አጠቃላይ ንብረቶች	148.89 ቢ	-34.49%
አጠቃላይ ተጠያቂነቶች	6.85 ቢ	-90.68%
አጠቃላይ እሴት	142.04 ቢ	—
የሼሮቹ ብዛት	46.05 ሚ	—
የገበያ ዋጋ እና የተገለጸ ዋጋ	0.88	—
የእሴቶች ተመላሽ	-2.10%	—
የካፒታል ተመላሽ	-2.19%	—

የገንዘብ ፍሰት

የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ

(KRW)	ዲሴም 2024	ከዓመት ዓመት ለውጥ
የተጣራ ገቢ	-1.96 ቢ	94.61%
ከክወናዎች የተገኘ ጥሬ ገንዘብ	-1.39 ቢ	68.41%
ገንዘብ ከኢንቨስትመንት	1.38 ቢ	111.33%
ገንዘብ ከፋይናንስ	-5.47 ሚ	-100.02%
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ	-363.50 ሚ	-101.86%
ነፃ የገንዘብ ፍሰት	-2.04 ቢ	-104.61%

ስለ

Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia

የተመሰረተው

ኖቬም 1996

ድህረገፅ

helixmith.com

ሠራተኞች